Recent Biosimilars Deals

Goodwin
Contact

Goodwin

On January 13, 2021, EVOQ announced a license and collaboration agreement with Amgen for the development of new drugs for autoimmune disorders.  According to the press release, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization.  Amgen’s portfolio includes biosimilars AMGEVITA (a HUMIRA biosimilar) and AVSOLA (a REMICADE biosimilar).

On January 18, 2021, Innovent Biologics, Inc. announced an agreement with PT Etana Biotechnologies Indonesia to out-license the development and commercialization rights of BYVASDA, Innovent’s bevacizumab Biosimilar, to Etana in Indonesia.  The press release indicates that “Innovent will receive milestones for development and commercialization as well as double-digit royalties on net sales.”  As previously reported, BYVASDA was first approved by China’s National Medical Products Administration for the treatment of advanced non-small cell lung cancer and metastatic colorectal cancer in June 2020.  In January 2020, Innovent out-licensed the commercial rights of BYVASDA in the United States and Canada to Coherus BioSciences.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.